SRP2152

Sigma-Aldrich

HIV Protease, His tagged,recombinant from HIV-1

recombinant, expressed in E. coli, ≥85% (SDS-PAGE)

Sinónimos:
HIV_retropepsin_like, pepsin-like aspartate proteases, Retropepsins, cd05482
NACRES:
NA.26
En este momento no podemos mostrarle ni los precios ni la disponibilidad

biological source

human immunodeficiency virus 1

recombinant

expressed in E. coli

assay

≥85% (SDS-PAGE)

form

frozen liquid

mol wt

~11.9 kDa

packaging

pkg of 10 μg

storage condition

avoid repeated freeze/thaw cycles

concentration

200 μg/mL

color

colorless to clear

NCBI accession no.

UniProt accession no.

shipped in

dry ice

storage temp.

−70°C

Categorías relacionadas

Application

HIV Protease has been used in in vitro detection of HIV protease activity using FRET-HIV Sensor, a Förster resonance energy transfer-based HIV protease-sensitive sensor.

Biochem/physiol Actions

The HIV-1 core consists of a viral genome housed within a conical viral capsid that is generated during virion maturation. Human immunodeficiency virus type 1 (HIV-1) matures after the viral protease processes the Gag and Pol polyproteins at 10 substrate locations. The protease of HIV-1 is an aspartic protease and is functional only as a dimer; dimerization results in the formation of a binding cleft in which each of the two catalytic aspartic acids is contributed by one of the monomers. Because the protease is active only as a dimer, two of the GagPol precursors must themselves dimerize during virus assembly so that their protease domains can dimerize, become active, and process the precursors. The order and kinetics of cleavage as well as the extent of precursor processing appear to be critical steps in the generation of fully infectious, appropriately assembled viral particles. Inhibition of HIV-1 protease represents an important avenue for antiviral therapy. Currently available combination chemotherapy with reverse transcriptase inhibitors (RTIs) and protease inhibitors (PIs) for human immunodeficiency virus type 1 (HIV-1) infection and AIDS have been shown to suppress the replication of HIV-1 and extend the life expectancy of HIV-1-infected individuals.

Sequence

PQITLWQRPL VTIKIGGQLK EALLDTGADD TVLEEMSLPG RWKPKMIGGI GGFIKVRQYD QILIEICGHK AIGTVLVGPT PVNIIGRNLL TQIGCTLNF

Physical form

Formulated in 20mM Mes buffer, pH6, 500mM KCl, 20% glycerol.
Clear and colorless frozen liquid solution

Preparation Note

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. While working, please keep sample on ice.
Please keep in −20 °C for long term storage. It lost 70% activity in 4°C for one week. Freeze thaw cycle resistance.

RIDADR

NONH for all modes of transport

WGK Germany

WGK 1

Flash Point F

Not applicable

Flash Point C

Not applicable

Certificado de Análisis
K C Chou et al.
Proteins, 24(1), 51-72 (1996-01-01)
Based on the sequence-coupled (Markov chain) model and vector-projection principle, a discriminant function method is proposed to predict sites in protein substrates that should be susceptible to cleavage by the HIV-1 protease. The discriminant function is defined by delta =...
C Peng et al.
Journal of virology, 63(6), 2550-2556 (1989-06-01)
It is generally believed that the gag gene product of human immunodeficiency virus type 1 (HIV-1) is processed into several core proteins by a virus-specific protease. We used deletion mutation analysis to study the role of HIV-specific protease in the...
Noninvasive high-throughput single-cell analysis of HIV protease activity using ratiometric flow cytometry.
Gaber R
Sensors (Basel, Switzerland), 13, 16330-16346 (2013)

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico

Redes sociales

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Investigación. Desarrollo. Producción.

Somos un proveedor líder para la industria de Ciencias de la Vida con soluciones y servicios para investigación, desarrollo y producción biotecnológicos, y para desarrollo y producción de tratamientos farmacéuticos

© 2021 Merck KGaA, Darmstadt, Alemania y/o sus filiales. Todos los derechos reservados.

Queda estrictamente prohibida la reproducción sin permiso de cualquiera de los materiales de la página web.